A detailed history of Douglas Lane & Associates, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Douglas Lane & Associates, LLC holds 2,545 shares of LLY stock, worth $1.99 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,545
Previous 2,622 2.94%
Holding current value
$1.99 Million
Previous $2.37 Million 5.01%
% of portfolio
0.03%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$772.14 - $960.02 $59,454 - $73,921
-77 Reduced 2.94%
2,545 $2.25 Million
Q2 2024

Jul 08, 2024

SELL
$724.87 - $909.04 $234,133 - $293,619
-323 Reduced 10.97%
2,622 $2.37 Million
Q1 2024

Apr 11, 2024

SELL
$592.2 - $792.28 $190,688 - $255,114
-322 Reduced 9.86%
2,945 $2.29 Million
Q4 2023

Jan 17, 2024

SELL
$525.19 - $619.13 $84,555 - $99,679
-161 Reduced 4.7%
3,267 $1.9 Million
Q3 2023

Oct 16, 2023

BUY
$434.7 - $599.3 $8,259 - $11,386
19 Added 0.56%
3,428 $1.84 Million
Q2 2023

Jul 19, 2023

SELL
$350.74 - $468.98 $701 - $937
-2 Reduced 0.06%
3,409 $1.6 Million
Q1 2023

Apr 17, 2023

BUY
$310.63 - $364.82 $53,117 - $62,384
171 Added 5.28%
3,411 $1.17 Million
Q4 2022

Jan 17, 2023

BUY
$321.55 - $374.67 $1,607 - $1,873
5 Added 0.15%
3,240 $1.19 Million
Q3 2022

Oct 14, 2022

SELL
$296.48 - $337.87 $25,200 - $28,718
-85 Reduced 2.56%
3,235 $1.05 Million
Q2 2022

Jul 18, 2022

SELL
$278.73 - $327.27 $34,562 - $40,581
-124 Reduced 3.6%
3,320 $1.08 Million
Q1 2022

Apr 25, 2022

SELL
$234.69 - $291.66 $96,926 - $120,455
-413 Reduced 10.71%
3,444 $986,000
Q4 2021

Jan 25, 2022

BUY
$224.85 - $279.04 $3,372 - $4,185
15 Added 0.39%
3,857 $1.07 Million
Q3 2021

Oct 21, 2021

SELL
$221.6 - $272.71 $87,088 - $107,175
-393 Reduced 9.28%
3,842 $888,000
Q2 2021

Jul 19, 2021

BUY
$180.55 - $233.54 $1,444 - $1,868
8 Added 0.19%
4,235 $972,000
Q1 2021

Apr 19, 2021

SELL
$164.32 - $212.72 $73,615 - $95,298
-448 Reduced 9.58%
4,227 $790,000
Q4 2020

Jan 14, 2021

SELL
$130.46 - $172.63 $9,001 - $11,911
-69 Reduced 1.45%
4,675 $789,000
Q3 2020

Oct 19, 2020

SELL
$146.22 - $169.13 $17,546 - $20,295
-120 Reduced 2.47%
4,744 $702,000
Q2 2020

Jul 28, 2020

BUY
$136.42 - $164.18 $55,522 - $66,821
407 Added 9.13%
4,864 $799,000
Q1 2020

Apr 20, 2020

SELL
$119.05 - $147.35 $144,645 - $179,030
-1,215 Reduced 21.42%
4,457 $618,000
Q4 2019

Jan 27, 2020

BUY
$106.92 - $132.43 $21,384 - $26,486
200 Added 3.65%
5,672 $745,000
Q3 2019

Oct 16, 2019

BUY
$106.79 - $116.16 $320 - $348
3 Added 0.05%
5,472 $612,000
Q2 2019

Jul 08, 2019

SELL
$110.79 - $129.32 $8,863 - $10,345
-80 Reduced 1.44%
5,469 $606,000
Q1 2019

Apr 23, 2019

SELL
$111.31 - $131.02 $16,696 - $19,653
-150 Reduced 2.63%
5,549 $720,000
Q4 2018

Jan 17, 2019

BUY
$105.9 - $118.64 $85,779 - $96,098
810 Added 16.57%
5,699 $659,000
Q3 2018

Oct 09, 2018

SELL
$85.86 - $107.31 $160,644 - $200,777
-1,871 Reduced 27.68%
4,889 $525,000
Q2 2018

Jul 23, 2018

BUY
$75.7 - $86.88 $511,732 - $587,308
6,760 New
6,760 $577,000
Q4 2017

Jan 24, 2018

SELL
$81.94 - $87.89 $194,607 - $208,738
-2,375 Closed
0 $0
Q3 2017

Oct 19, 2017

BUY
$77.07 - $85.54 $183,041 - $203,157
2,375
2,375 $203,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $744B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Douglas Lane & Associates, LLC Portfolio

Follow Douglas Lane & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglas Lane & Associates, LLC with notifications on news.